http://www.proactiveinvestors.com Proactiveinvestors RSS feed en Sun, 24 Jun 2018 14:52:06 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - Pressure BioSciences has an eye toward uplisting as it strengthens balance sheet ]]> http://www.proactiveinvestors.com/companies/stocktube/9648/pressure-biosciences-has-an-eye-toward-uplisting-as-it-strengthens-balance-sheet-9648.html Thu, 21 Jun 2018 11:26:00 -0400 http://www.proactiveinvestors.com/companies/stocktube/9648/pressure-biosciences-has-an-eye-toward-uplisting-as-it-strengthens-balance-sheet-9648.html <![CDATA[News - 'We run Pressure BioSciences as if we were on Nasdaq or NYSE,' says CEO ]]> http://www.proactiveinvestors.com/companies/news/199064/-we-run-pressure-biosciences-as-if-we-were-on-nasdaq-or-nyse-says-ceo-199064.html Richard T Schumacher, CEO of Pressure BioSciences Inc (OTCMKTS:PBIO) said Monday that the company continues to strengthen its balance sheet by converting a “significant amount” of debt into equity.

He said that with shrinking debt, the life-sciences company plans to uplist to a national exchange before the end of the year.

“Although we are a QB company on the OTC Marketplace, we run the company as if we were NASDAQ or NYSE-Amex listed. This is important, since we have expectations of moving up to a national stock exchange before the end of this year,” Schumacher told the “Stock Day Podcast” on the Uptick Network Radio.  

The Harvard Medical School-trained serial entrepreneur said Pressure BioSciences has been “working diligently” to meet the requirements necessary to uplist to a national exchange.

On June 12, the company converted an additional US$7.24mln of debt into equity, bringing the total amount of debt that it has converted into equity over the past four weeks to more than US$13.6mln.

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground. 

READ: Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

“We’re changing a paradigm that’s existed in labs for maybe 50 years,” said Schumacher.

Many other extraction methods used by over 500,000 researchers worldwide involve breaking cells open in more volatile ways that can actually damage the biomolecule contents or put researchers at risk.

PBI’s unique technology is more like squeezing a sponge, and the number of squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in research.

“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really no way of safely getting high pressure into the lab,” Schumacher told the “Stock Day Podcast.” 

“We use pressures up to six times the pressure you would feel if you were standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure,” he said.

Schumacher went on to tell the podcast that their pressure chambers can “safely reach levels up to 100,000 PSI, a staggering high” in the industry.

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to more than 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Investment case

The Stock Day Podcast host Everett Jolly noted that with a market cap of about US$4.2mln and shares selling at just under US$3 it was a “great time for investors” to get a look at Pressure BioSciences.

“It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors are always looking. The company has done very well over the past 18-24 months, and we expect they will continue to do well, yet their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly.

“Until then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”

Shares of the company were up 2.56% to US$4 in morning trading.

 

]]>
Mon, 18 Jun 2018 10:29:00 -0400 http://www.proactiveinvestors.com/companies/news/199064/-we-run-pressure-biosciences-as-if-we-were-on-nasdaq-or-nyse-says-ceo-199064.html
<![CDATA[News - Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity ]]> http://www.proactiveinvestors.com/companies/news/198715/pressure-biosciences-invigorates-its-balance-sheet-converts-additional-us724mln-of-debt-into-equity-198715.html Pressure BioSciences Inc (OTCMKTS:PBIO) continued to strengthen its balance sheet Tuesday with the conversion of an additional US$7.24mln of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to more than US$13.6mln.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, it would increase the life sciences company’s chance of uplisting to a national exchange, such as Nasdaq, later this year.

“We are continuing to discuss the company's progress with remaining debt holders, and anticipate that several more may follow the lead of the approximate 40-plus investors who converted their debt into equity over the past 30 days,” said Pressure BioSciences CFO Joseph L. Damasio. "We believe such further conversions could reduce the amount of loan debt on our balance sheet by an additional 10% to 15%," he added.

READ: Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground.  

“We are very pleased to have been able to clean up the balance sheet as much as we have over the past 30 days,” Pressure BioSciences CEO Richard Schumacher said in an emal to Proactive Investors. “Of course, there is more work to be done, which we are excited to be tackling.”

Schumacher noted that the company had successfully accessed debt for working capital. “This has allowed us to increase revenue, enlarge our customer base, enhance our instrument and consumables line, expand our sales and marketing reach, add much-needed manufacturing and development space, and strengthen other internal operational areas.”

He said that at a “strategic level,” debt capital had allowed the company to attain “initial progress and IP issuances” in its new Ultra Shear Technology platform, and to acquire all of BaroFold Corp.'s assets.

“We believe that both of these strategic programs will bring about substantial expansion in major new business segments,” said Schumacher.

The Harvard Medical School trained serial entrepreneur who has founded four companies is extremely enthusiastic about the first contract Pressure BioSciences has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher had earlier told proactive investors. “It’s all coming together this year.”

WATCH: Pressure BioSciences CEO sees increased revenue on projects and services in 2018

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to over 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Focus on uplisting to a national exchange

Meanwhile, Jeffrey N. Peterson, chairman of the board, said the conversion of “a majority of our loan debt into equity” would help Pressure BioSciences in its quest to uplist to a national exchange.

"We believe Pressure BioSciences Inc’s recent accomplishments, when combined with the conversion of a majority of our loan debt into equity, will materially facilitate progress towards our stated objective of uplisting to a national exchange (NASDAQ, NYSE/Amex) later in 2018,” said Peterson.

“We believe a national exchange trading platform will provide improved access to capital and trading volumes, and that these should result in a more attractive and higher-value recognition level for the company, benefitting all shareholders," he added.

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in the area of high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

Pressure Biosciences' shares traded flat amid a broader market pullback.

]]>
Tue, 12 Jun 2018 10:29:00 -0400 http://www.proactiveinvestors.com/companies/news/198715/pressure-biosciences-invigorates-its-balance-sheet-converts-additional-us724mln-of-debt-into-equity-198715.html
<![CDATA[Media files - Pressure BioSciences CEO sees increased revenue on projects and services in 2018 ]]> http://www.proactiveinvestors.com/companies/stocktube/9331/pressure-biosciences-ceo-sees-increased-revenue-on-projects-and-services-in-2018 Fri, 18 May 2018 11:42:00 -0400 http://www.proactiveinvestors.com/companies/stocktube/9331/pressure-biosciences-ceo-sees-increased-revenue-on-projects-and-services-in-2018 <![CDATA[News - Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum ]]> http://www.proactiveinvestors.com/companies/news/197230/callitas-health-chemiocare-and-pressure-biosciences-make-a-splash-at-proactive-investors-forum-197230.html Three companies blazing fresh tracks with unprecedented mechanisms and novel medicines made a splash at Proactive Investors’ Biotech and Life Sciences conference in New York on Wednesday.    

It's a great adrenaline-filled time to be in biotech, and the scientific entrepreneurs spearheading Callitas Health Inc. (CNSX:LILY), ChemioCare USA Inc and  Pressure BioSciences Inc (OTCMKTS:PBIO) shared their stories in an event held Wednesday evening at the 3 West Club in New York City.

The presentations by the three CEOs was met with enthusiasm by a full house of institutional and retail investors, high net-worth individuals, fund managers and analysts.

Investors perked up as the companies talked about clinical trial results and potential orphan drugs that offer rare opportunities to make money.

“Biotechs are still popular with investors for all the right reasons: there’s a lot of M&A activity, solid clinical data, regulatory reviews, upcoming scientific conferences and orphan drugs,” said Sheldon S. Traube at Kareg Research, who attended the event. “They offer so much opportunity.”

Patching the problem of chemo-induced nausea

The biopharma sector is discovering and developing new transformative therapies for patients across a huge range of diseases.

In March, industry veteran Pedro Lichtinger and Dr. Fotios Plakogiannis, who operates a lab in Long Island City, bootstrapped a biotech start-up called ChemioCare USA Inc. It’s working on novel skin patch technology for treating chemo-induced nausea and vomiting.

It leverages transdermal technology using adhesive patches to deliver medicines through the skin. ChemioCare’s product pipeline includes four different single active ingredient patches using proprietary formulations. Its chemio-ondan patch which delivers a sustained dose over three to five days is furthest along the development process.

The company is also working on a combination patch involving a mixture of two or three agents dosed over to two-to-five days.

“The revenue potential of each patch is between US$400mln and US$1bn,” pointed out ChemioCare CEO Pedro Lichtinger, who has an MBA from Wharton and an engineering degree from the National University of Mexico.

“Compared to new molecular entity drug development, ChemioCare is low risk, fast to market with limited capital needs. We are reformulating well known generic drugs with the objective of achieving on label meaningful improvements,” he added.

The CEO said the biotech’s development programs “are designed to follow the 505(b)2 pathway” and require a relatively low financial investment.

In plain terms, a company using the 505(b)(2) FDA drug approval pathway relies on clinical data or literature produced by other companies.

Eyes set on IPO in 10 months

Lichtinger, who has an impressive 37-year career in biotechnology, is taking the up-and-coming biotech public by March 2019.

“In 10 months, we will be in a position to launch an IPO. We are going to do a dual listing in Nasdaq and Canada,” said Lichtinger who has a proven track record of building commercial and R&D capabilities at aspiring companies that need cash to develop.

WATCH: ChemioCare plans IPO and raise funds to bring 'transformative' drug to the market

No stranger to taking companies public, Lichtinger was formerly the CEO of Asterias Biotherapeutics Inc. (NYSEAMERICAN:AST) and Optimer Pharmaceuticals Inc (NASDAQ:OPTR). He also has a 16-year stint with Pfizer Inc. under his belt.

“I think there will be terrific demand for ChemioCare’s patches because the existing regimens have a lot of side effects. There’s significant unmet medical need,” said Irma Calara Nielson, a savvy investor looking for ground-floor investments.

Callitas Health focuses on innovation

Callitas Health, a clinical-stage company focused on weight management and female health, has big plans for a broad product portfolio. It is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.

In February, it hired Freyeur & Trogue (F&T) to provide development consulting to help optimize its large product portfolio development and commercialization.

“We have two blue sky assets which have massive revenue potential,” said Interim Callitas Health CEO James Thompson.

Notably, late last year, Callitas received a successful response from the US FDA on its pre-investigational new drug (IND) application for its Extrinsa topical gel to treat female sexual dysfunction (FSD).

Sitting pretty on a large market

Thompson said that Extrinsa could be a US$1bn opportunity. Addyi, the only drug currently approved for the treatment of female sexual desire disorder was purchased by Valeant Pharmaceuticals International Inc (NYSE:VRX) from Sprout for more than US$1bn in 2016.

Valeant had estimated that sales would ramp up to US$1bn annually for this drug, and it makes no claims to treat orgasm disorders, so the potential market for Extrinsa should be higher.

The company is also working on C – 103, the reformulated weight loss treatment, which was Orlistat (which had unwelcome side effects). The firm has targeted US$500mln in revenue from C-103 from the US market alone as first-year revenues, once it is approved by the FDA.

“We have patent-pending pharmaceutical status from the US patent office concerning the orally dissolvable delivery technology concerning cannabinoids branded as CannaMint Strips by Callitas,” said Thompson.

The firm is planning to license the technology to manufacturers and distributors in North America.

The company recently signed partnership agreements with two undisclosed Californian companies, which permits Calitas to market and sell its CannaMint strips for both tetrahydrocannabinol (thc) and cannabidiol (cbd).

2018 is the year for Pressure BioSciences

Serial entrepreneur Richard Schumacher, who is the CEO of Pressure BioSciences Inc (OTCMKTS:PBIO), expects 2018 to be a “banner year” for the firm.

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to over 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

“We have expanded our sales force from one to five and this will boost our 2018 revenue,” said Schumacher.

Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

The Harvard Medical School trained serial entrepreneur who has founded four companies is extremely enthusiastic about the first contract Pressure BioSciences has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” said Schumacher. “It’s all coming together this year.”

A sixth sense for biotech can make investors a lot of money as the margins are high and the opportunities are very big.   

“All three companies had exciting technologies in emerging growth areas and they are all looking to take new technologies to market or improving existing technologies,” said Kevin McGarth of strategic advisory firm TraDigital IR, who attended the event.

 

]]>
Thu, 17 May 2018 16:34:00 -0400 http://www.proactiveinvestors.com/companies/news/197230/callitas-health-chemiocare-and-pressure-biosciences-make-a-splash-at-proactive-investors-forum-197230.html
<![CDATA[News - Pressure BioSciences shares soar on shrinking debt and jump in first-quarter revenue ]]> http://www.proactiveinvestors.com/companies/news/197036/pressure-biosciences-shares-soar-on-shrinking-debt-and-jump-in-first-quarter-revenue-197036.html Investors sent shares of Pressure BioSciences Inc (OTCMKTS:PBIO) soaring Tuesday after the life science group reported both a jump in first-quarter revenue thanks to an uptick in instrument sales, and said it has shrunk its debt.

By the afternoon, Pressure Bio's shares were up about 19% to US$3.90.

The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks partly to booming sales of the company’s laboratory instruments which utilize pressure to control bio-molecular interactions.

Sales of instruments jumped 8% to $420,089 in the first quarter compared with $396,095 last year while sales of related consumables rose 18% to $74,698 compared with $63,264 for the same period in 2017.

Pressure BioSciences also successfully converted US$6.39mln worth of debentures held by 22 debt holders into series AA preferred stock, which means that it paid off 92% of its 2015/2016 outstanding debenture debt on its balance sheet as of the end of last March.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, CEO Richard Schumacher says it would increase the company’s chance of uplisting to a national exchange such as the Nasdaq later this year.“We are in discussions with other note-holders about the possible conversion of debt into equity in the near future,” said Schumacher in a statement. “If some of these additional loans are also converted into equity, the projected balance sheet on June 30, 2018, will be materially stronger than the balance sheet as of March 31, 2018."

READ: Pressure Biosciences chief bullish on sale of new PreEMT platform

As a result of its move to pay down its debt and the bolstering of its revenue, the company’s loss shrank 24% to US$1.64 in the first quarter, down from a loss of US$2.16 in the year-ago quarter.

Among wins in the quarter is the signing of the first contract to evaluate the ability of the company’s patented PreEMT platform to improve the manufacturing process for protein therapeutic drug candidates.

Pressure BioSciences also entered a two-year global co-marketing and distribution agreement with ISS Inc, a supplier of high-pressure optical cell systems used for laboratory analysis. Working together, the two companies plan to replace ISS’s manual pressure generator with Pressure BioSciences’ computer-controlled, automated instruments.

]]>
Tue, 15 May 2018 13:31:00 -0400 http://www.proactiveinvestors.com/companies/news/197036/pressure-biosciences-shares-soar-on-shrinking-debt-and-jump-in-first-quarter-revenue-197036.html
<![CDATA[News - Pressure Biosciences chief bullish on sale of new PreEMT platform ]]> http://www.proactiveinvestors.com/companies/news/196748/pressure-biosciences-chief-bullish-on-sale-of-new-preemt-platform-196748.html Richard Schumacher, president and chief executive of Pressure BioSciences Inc. (OTCQB:PBIO), is extremely enthusiastic about the first contract the group has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher noted in an interview held as part of the “Stock Day” podcast. “We view this as both significant and exciting and believe that additional contracts will soon be secured.”

In addition to the recent contract reached with the biopharma company, two other protein-based biotherapeutic companies have approached Pressure Biosciences in the last several weeks to ask about potential collaborations with similar studies.

READ: Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

PreEMT technology improves the quality of manufacturing biopharma products and decreases manufacturing costs by as much as US$2mln to US$10mln per year for each commercial biologic drug.

Hundreds of labs already utilize Pressure Bioscience's pressure-based systems – which take advantage of pressure cycling technology – to extract proteins from all types of cells, whether it be plant, animal or human and whether the cells are normal or cancerous.

Pressure Biosciences has developed three new lab instruments that will be released within the next year and Schumacher is bullish about the company’s outlook for the year. “We are very excited about the potential of 2018 – we see this year shaping up well,” he said on the “Stock Day” podcast.

Pressure Biosciences shares closed up 5.7% to US$3.70 on Wednesday.

]]>
Thu, 10 May 2018 08:30:00 -0400 http://www.proactiveinvestors.com/companies/news/196748/pressure-biosciences-chief-bullish-on-sale-of-new-preemt-platform-196748.html
<![CDATA[News - Pressure BioSciences reaches a deal to contract out its PreEMT platform ]]> http://www.proactiveinvestors.com/companies/news/196371/pressure-biosciences-reaches-a-deal-to-contract-out-its-preemt-platform-196371.html Pressure BioSciences Inc (OTCMKTS:PBIO), a life-science group that makes instruments which utilize pressure to control bio-molecular interactions, has signed a deal with an unnamed international biopharmaceutical company, which will assess the potential of its PreEMT platform.

The hope is that the PreEMT platform – which uses high pressure to help drug companies develop protein-based therapeutics - can be used to manufacture and improve the quality of a key protein-based drug, which is currently under development at the undisclosed biopharmaceutical group.

The manufacture of therapeutic proteins is difficult and complex and producing a typical protein drug may include more than 5,000 steps. As a result, even in the best laboratories, it is typical for protein therapeutics to fail in manufacturing.   

“We believe this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality novel protein therapeutics and lower the cost of existing formulations," said Dr. Alexander Lazarev, vice president of research & development. “PreEMT can be applied to many therapeutic proteins. … It is scaleable and practical for standard manufacturing processes.”

READ: Pressure BioSciences CEO says company poised for 'solid year' in 2018

Richard Schumacher, Pressure BioScience’s president and chief executive, said the contract with the international biopharma group will be wrapped up in three to four months.  He noted that several other biopharmaceutical companies are interested in evaluating the group’s PreEMT platform and said that if deals are done, Pressure BioScience will receive royalty revenues.

“Should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue,” Schumacher said.

There are over 200 therapeutic proteins and peptides now approved for clinical use in the U.S. These drugs have changed therapy options for cancer and blood disorders and are also a treatment option for autoimmune diseases.

Pressure BioScience’s shares were flat at US$3.75 in early afternoon trade.

]]>
Thu, 03 May 2018 12:02:00 -0400 http://www.proactiveinvestors.com/companies/news/196371/pressure-biosciences-reaches-a-deal-to-contract-out-its-preemt-platform-196371.html
<![CDATA[News - Pressure BioSciences CEO says company poised for 'solid year' in 2018 ]]> http://www.proactiveinvestors.com/companies/news/194662/pressure-biosciences-ceo-says-company-poised-for-solid-year-in-2018-194662.html Pressure BioSciences Inc. (OTCQB:PBIO) Chief Executive Officer Richard T. Schumacher said he expects 2018 to be “another solid year” for the Massachusetts-based company, helped in part by the acquisition of BaroFold intellectual property.

“The results we achieved in 2017 were especially rewarding in that they were achieved with only one dedicated salesperson,” Schumacher said recently on Uptick Newswire’s “Stock Day” podcast. “The enhancements we are implementing in our products, our sales and marketing capabilities, and our corporate infrastructure will allow us to better design, create, sell, support and distribute our product line in 2018.”

READ: Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business

The life-science group that makes laboratory devices said last week that fourth-quarter sales gained 20% as its product and services business continues to grow. Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The CEO also cited new patents in Pressure BioSciences’s Ultra Shear Technology platform and the release of its GMP-compliant software as areas that will contribute to results this year.

“We believe these new assets will help expand our customer base, take us further down the path to profitability and help increase shareholder value,” Schumacher said.

]]>
Tue, 10 Apr 2018 11:56:00 -0400 http://www.proactiveinvestors.com/companies/news/194662/pressure-biosciences-ceo-says-company-poised-for-solid-year-in-2018-194662.html
<![CDATA[News - Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business ]]> http://www.proactiveinvestors.com/companies/news/194189/pressure-biosciences-reports-20-bump-in-4q-sales-expects-continued-growth-in-its-main-business-194189.html Pressure BioSciences Inc. (OTCMKTS:PBIO), a life-science group that makes laboratory devices, saw a 20% bump in sales for the fourth quarter as its product and services business continues to grow.

Revenue in the period grew to US$502,708, helped by the product and services unit, which expanded by 25%. Revenue for 2017 climbed as well, to US$2.2mln from US$1.9mln a year earlier.

Chief Executive Officer Richard Schumacher said in March that the firm is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc.

READ: Pressure BioSciences chief presents rosy view of growth prospects in podast interview

Pressure BioSciences, which makes instruments that utilize pressure to control bio-molecular interactions, said in a statement Tuesday that accompanied its fourth-quarter earnings that it expects “continued double-digit” growth rates in its product and services business.

“We believe the accomplishments of the past several years have set the stage for future success,” Schumacher said. “We remain very, very excited about 2018.”

While operating loss widened in the fourth quarter, it was on higher expenses linked to expanding the company’s sales team, the Massachusetts-based firm said in a statement. The loss per common share was US$2.37 vs. income of US$3.13 a share in the year-earlier period.

Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The shares added 1.3% to US$3.80 as of 1:10 p.m. on Thursday.

]]>
Thu, 05 Apr 2018 13:12:00 -0400 http://www.proactiveinvestors.com/companies/news/194189/pressure-biosciences-reports-20-bump-in-4q-sales-expects-continued-growth-in-its-main-business-194189.html
<![CDATA[News - Pressure BioSciences chief presents rosy view of growth prospects in podast interview ]]> http://www.proactiveinvestors.com/companies/news/193096/pressure-biosciences-chief-presents-rosy-view-of-growth-prospects-in-podast-interview-193096.html Richard Schumacher, chief executive of Pressure BioSciences Inc (OTCMKTS:PBIO), a Massachusetts-based life science group which makes laboratory devices, is on the road, touting the expansion of the firm’s business.

The chief of this maker of instruments which utilise pressure to control bio-molecular interactions said his company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc., an Illinois-based designer of scientific instruments.

Schumacher said on Tuesday in an interview with Uptick Newswires "Stock Day" podcast: “We believe we have set the table to facilitate even greater revenues with the deployment of an experienced, trained, and dedicated field sales team, the acquisition of the BaroFold, Inc. assets – including 8 important patents that integrate well with our own seventeen patents, and our very recently announced co-marketing and distribution relationship with ISS Inc.”

Pressure BioSciences reached the two-year agreement with ISS last month.

One of the products ISS makes is a spectrophotometer -- an instrument used in drug discovery and development -- the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As its name suggests, Pressure Bio, meanwhile, manufactures automated pressure generators for laboratories which can increase and decrease pressure “like a light switch.”

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000 and US$50,000 each.

The company doesn’t sell many of these units at the moment, Schumacher said last month, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

In midday trading, shares of the company were flat at US$4.80.

]]>
Tue, 13 Mar 2018 09:55:00 -0400 http://www.proactiveinvestors.com/companies/news/193096/pressure-biosciences-chief-presents-rosy-view-of-growth-prospects-in-podast-interview-193096.html
<![CDATA[News - Pressure BioSciences expecting sales boost from new co-marketing deal with ISS ]]> http://www.proactiveinvestors.com/companies/news/191662/pressure-biosciences-expecting-sales-boost-from-new-co-marketing-deal-with-iss-191662.html Pressure BioSciences Inc (OTCQB:PBIO) has signed a two-year worldwide co-marketing and distribution agreement with Illinois-based medical instruments maker ISS.

One of the products ISS makes is a spectrophotometer - an instrument used in drug discovery and development - the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As it name suggests, Pressure Bio manufactures automated pressure generators which can increase and decrease pressure “like a light switch”.

‘If you buy this, you should buy this too’

The two companies have been in talks for a little while about bringing their two systems together and after Wednesday's tie-up they will actively look to market each other’s devices.

“We are going to sell our equipment...to customers that reach out to us and we will then let [the customers] know that they can talk directly to [ISS] about buying the spectrophotometer from them,” said PBIO President and chief executive Richard Schumacher in a conference call.

“If [ISS] gets requests coming in they will either shuttle them to us or sell the pressure cell and the spectrophotometer and then send [the customer details] to us to sell the pressure generating equipment.”

Pressure’s VP marketing and sales, Nate Lawrence, added: “The unique combination of PBI’s high pressure generators and ISS’s high pressure optical cell system is expected to greatly benefit scientists in academic institutions, industry and governments who study biological samples and processes at the molecular level.”

Tie-up should increase sales

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000-US$50,000 each.

The company don’t sell many of these units at the moment, Schumacher said, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

Pressure Bio and ISS will both be at the Biophysical Society in San Francisco this weekend, where both parties will talk about their new partnership.

Shares were flat at US$3.85 on Wednesday.

]]>
Wed, 14 Feb 2018 11:20:00 -0500 http://www.proactiveinvestors.com/companies/news/191662/pressure-biosciences-expecting-sales-boost-from-new-co-marketing-deal-with-iss-191662.html
<![CDATA[News - Pressure BioSciences expecting banner year for the company in 2018 ]]> http://www.proactiveinvestors.com/companies/news/190776/pressure-biosciences-expecting-banner-year-for-the-company-in-2018-190776.html Pressure BioSciences Inc's (OTCMKTS:PBIO) boss Richard Schumacher expects 2018 to be a “banner year” for the firm.

In a 'Stock Day' podcast Schumacher ran through a number of aspects of recent progress, including that it had sold more PCT (pressure cycling technology) machines in the third quarter of 2017 than it had ever sold in a single quarter before.

Revenues for the firm's products and services increased 21% in that quarter alone, with consumable products increasing 158% - the largest increase in consumables the firm ever reported.

Schumacher also said a big multinational company, who was a customer, had also been working with Pressure to produce a software upgrade for its flagship Barocycler 2320EXTREME instrument.

Pressure believes this new instrument will now be "highly desirable" in its niche life sciences and pharmaceutical markets.

Also discussed was the newly established Center of Excellence in China, which will showcase three of the company's PCT instruments and many related consumable products.

"Being the first Center of Excellence in Asia, the company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements," said Schumacher.

The firm's acquisition of BaroFold Inc had increased the IP (intellectual property) estate of the company by eight issued and several pending patents, and had allowed the company to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation, he added.

Watch the Podcast HERE...

]]>
Mon, 29 Jan 2018 13:07:00 -0500 http://www.proactiveinvestors.com/companies/news/190776/pressure-biosciences-expecting-banner-year-for-the-company-in-2018-190776.html
<![CDATA[News - Pressure BioSciences says software upgrade enhances Barocycler 2320EXT instrument ]]> http://www.proactiveinvestors.com/companies/news/189111/pressure-biosciences-says-software-upgrade-enhances-barocycler-2320ext-instrument-189111.html Pressure BioSciences Inc (OTCMKTS:PBIO) says its redesigned software for its pressure-based Barocycler 2320EXTREME instrument will "significantly" expand its uses and appeal in the biopharma market.

The enhancement makes the 2320EXT device one of the few good manufacturing practices (GMP) compliant sample preparation systems available in the worldwide life sciences market today, the company said.

READ - Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

The machine is mainly used to prepare samples (tissues, cells, proteins) for analysis and has been installed in research and manufacturing laboratories worldwide.

"GMP compliance is not only mandated by the U.S. Food and Drug Administration and equivalent regulatory bodies worldwide, it is also widely accepted by the world's biopharmaceutical companies as the best - if not the only - way to bring a new product to market," noted Dr Alexander Lazarev, the vice president of R&D (research and development) at  Pressure BioSciences.

GMP covers all aspects of production, from starting materials to the final released product.

Having GMP-compliant features should allow the Barocycler 2320EXT to be used in multiple departments within the same company, and for multiple applications, said the US-listed firm.

Sample preparation is often complex, time-consuming, and one of the most error-prone steps in research.

READ - Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

It is also a large and growing market, estimated currently at US$6 billion worldwide.

It's been a busy month for Pressure BioSciences.

It has announced the acquisition of all assets of BaroFold Inc, which is expected to enhance revenues and increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

]]>
Wed, 20 Dec 2017 11:51:00 -0500 http://www.proactiveinvestors.com/companies/news/189111/pressure-biosciences-says-software-upgrade-enhances-barocycler-2320ext-instrument-189111.html
<![CDATA[News - Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018 ]]> http://www.proactiveinvestors.com/companies/news/188823/pressure-biosciences-expects-barofold-inc-to-have-significant-impact-on-revenues-in-2018-188823.html Pressure BioSciences Inc (OTCMKTS:PBIO) says its acquisition of all assets of BaroFold Inc is expected to enhance revenues and will increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

Pressure BioSciences has developed unique and superior pressure cycling technology (PCT) to prepare biological lab samples.

"This acquisition will significantly increase PBI's IP estate in high-pressure technologies with the addition of eight issued and several pending patents," said Alexander Lazarev, vice-president of R&D for PBI.

"These patents give us freedom to operate in several important areas for biologics research and manufacturing: protein folding, re-folding and disaggregation.

"They also provide us the right to grant licenses to third parties to practice the PreEMT and other technologies in both research laboratories and in biopharmaceutical manufacturing, the latter being a very large and rapidly growing field."

Dr Nathan Lawrence, of Pressure BioSciences, added: "Importantly, our existing high-pressure equipment is well-suited to the performance of the R&D and process development studies needed for the development of these biopharmaceutical manufacturing applications and markets.

"In fact, it will quickly become evident that our new, award-winning Barocycler 2320EXT high-pressure instrument was designed with technologies like PreEMT bench scale R&D in mind.

"With our worldwide customer base, supported by our expanded sales and marketing capabilities and our growing equipment and consumables product lines, we believe the newly-acquired BaroFold IP will have a significant impact on our revenues in 2018 and beyond."

Pressure BioSciences shares are down 4.50% to US$3.82 in New York.

]]>
Thu, 14 Dec 2017 12:22:00 -0500 http://www.proactiveinvestors.com/companies/news/188823/pressure-biosciences-expects-barofold-inc-to-have-significant-impact-on-revenues-in-2018-188823.html
<![CDATA[News - Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share ]]> http://www.proactiveinvestors.com/companies/news/187932/zacks-upbeat-on-pressure-biosciences-growth-potential-targets-us10-a-share-187932.html Pressure BioSciences Inc (OTC:PBIO) has received an upbeat write-up from Zacks smallcap research, which it reckons is more like a development stage biotech and targets US$10 each for the shares (current price: US$4.20).

The group operates in the "rather large, but underserved" research services market, says Zacks.

It has developed a "unique and superior pressure" cycling technology (PCT) to prepare biological laboratory samples.

The research group said sales had not been stellar so far, but this was "understandable".

PCT quite a new technology

"Pressure cycling technology is quite new to most customers in the sample preparation market, and the costs for PCT are also higher than those for most existing technologies. Therefore, rollout of the PCT platform will take time."

Earlier this month,  Pressure said it was moving firmly towards profitability as it unveiled record revenues for the third quarter.

It reckons this revenues growth will not only continue in the fourth quarter and beyond, but accelerate to a greater rate as new sales team begins to meet with existing and potential customers throughout the US.

Total revenue in the third quarter was up 21% to US$646,061 from US$535,334 in the same period last year, which was a new record for any quarter.

Products  and services revenue increased 21%  to US$603,726, a new quarterly record, while consumable sales increased 158% to US$84,594, again a new quarterly record.

Grant revenue increased 23% to US$42,335 in the quarter, versus 34,385 in the third quarter last year.

So far, and significantly, fourth quarter purchase orders and purchase indications (90% estimated probability of closing) through to early November have already exceeded products and services revenue for the full 2016 fourth quarter, Pressure also noted.

Poised to boost top and bottom line..?

In its note, Zacks said: "With a rapidly growing market worldwide, combined with its unique technology and broad range of product offering, the company is well positioned to boost its top line and bottom line in the coming years.

"According to our long term financial model, the company's products and services revenue will grow at a compound annual growth rate (CAGR) of 79% in the next four fiscal years from 2017 to 2020."

Pressure Biosciences will become profitable in fiscal 2019 with an EPS of $0.01, it adds.

Achieving the CE marking for the Barocycler 2320EXT in February was an important next step in the company' s commercialization plans for this powerful and enabling sample preparation instrument, highlights Zacks.

"The company recently signed agreements with several strong distribution partners in Europe, the SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe."

And now with a significantly expanded sales capabilities, as well as the newly established multinational co-marketing partner SCIEX, Zacks reckons revenue will grow significantly in the fourth quarter and beyond.

Our price target values the company at $11 million in market cap.

Valuation conservative..

"This valuation is still very conservative in our view. As long as the company can execute on its growth strategy correctly, we believe this goal is achievable. Patient investors will get rewarded."

Shares eased 1.18% to US$4.20 on Tuesday.

]]>
Tue, 28 Nov 2017 15:36:00 -0500 http://www.proactiveinvestors.com/companies/news/187932/zacks-upbeat-on-pressure-biosciences-growth-potential-targets-us10-a-share-187932.html
<![CDATA[News - Pressure BioSciences moves towards profitability as it reveals strong revenue growth in latest quarter ]]> http://www.proactiveinvestors.com/companies/news/187254/pressure-biosciences-moves-towards-profitability-as-it-reveals-strong-revenue-growth-in-latest-quarter-187254.html Pressure BioSciences Inc (OTCMKTS:PBIO) says it's moving firmly towards profitability as it unveiled record revenues for the third quarter.

The pressure cycling specialist said it reckons this growth in revenues will not only continue in the fourth quarter and beyond, but accelerate to a greater rate as new sales team begins to meet with existing and potential customers throughout the US.

" We have spent a lot of time and money over the past few years preparing for this opportunity. We believe we are ready and taking all necessary actions to grow our momentum and fully exploit the exciting growth and new markets potential that we have long envisioned," Richard T. Schumacher, president and chief executive, said.

The life sciences group develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market.

Total revenue in the third quarter was up 21% to US$646,061 from US$535,334 in the same period last year, which was a new record for any quarter.

Products  and services revenue increased 21%  to US$603,726, a new quarterly record, while consumable sales increased 158% to US$84,594, again a new quarterly record.

Grant revenue increased 23% to US$42,335 in the quarter, versus 34,385 in the third quarter last year.

So far, and significantly, fourth quarter purchase orders and purchase indications (90% estimated probability of closing) through to early November have already exceeded products and services revenue for the full 2016 fourth quarter, Pressure noted.

Operational highlights of the quarter just gone included the receipt of the first two issued patents on the high pressure-based Ultra Shear Technology (UST).

The firm also established its first Center of Excellence in Asia, expected to significantly impact PBI's expansion into China.

]]>
Tue, 14 Nov 2017 12:37:00 -0500 http://www.proactiveinvestors.com/companies/news/187254/pressure-biosciences-moves-towards-profitability-as-it-reveals-strong-revenue-growth-in-latest-quarter-187254.html
<![CDATA[News - Pressure BioSciences bidding to expand into large Chinese life sciences market ]]> http://www.proactiveinvestors.com/companies/news/186676/pressure-biosciences-bidding-to-expand-into-large-chinese-life-sciences-market-186676.html Pressure BioSciences Inc (OTCMKTS:PBIO) is bidding to take its sample preparation technology into the large life sciences market in China.

It comes as professor Tiannan Guo's laboratory at Westlake Institute for Advanced Study (WIAS) has been named as Pressure's first Center of Excellence (CoE) in China.

Guo and  Professor Ruedi Aebersold in Switzerland are co-developing PCT-SWATH, which is a novel method, which combines Pressure BioSciences' patented pressure cycling technology (PCT) platform with cutting-edge analytical capabilities of SCIEX's mass spectrometry SWATH method.

SCIEX, the life sciences tech firm, signed an exclusive co-marketing agreement with the firm in early 2016 to improve protein quantitation in complex samples.

"We are very pleased that Professor Guo will be leading the effort to establish and then direct our first CoE in China, " said Dr Nate Lawrence, vice president of marketing and sales.

"This Center is the first of its kind in Asia and joins our other Centers of Excellence in Europe and Australia as an important pillar in our global marketing and sales strategy.

"We believe Professor Guo's vast experience with the PCT platform, his expertise in proteomics and lipidomics, and his fluency in both Chinese and English will be invaluable in helping PBI quickly and successfully expand into the large life sciences market in China."

Guo added: "I believe strongly that PCT will have a significant impact in helping research scientists in China and around the world make new discoveries in multiple fields, including proteomics, genomics, lipidomics, and metabolomics."

Pressure BioSciences Inc shares were unchanged at US$3.94 at the time of writing.

]]>
Thu, 02 Nov 2017 10:28:00 -0400 http://www.proactiveinvestors.com/companies/news/186676/pressure-biosciences-bidding-to-expand-into-large-chinese-life-sciences-market-186676.html
<![CDATA[News - Pressure BioSciences' Schumacher upbeat on market potential for its life science tools ]]> http://www.proactiveinvestors.com/companies/news/186218/pressure-biosciences-schumacher-upbeat-on-market-potential-for-its-life-science-tools-186218.html Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher told a recent interview in New York that he believes the market opportunity for the group's tools, which prepare samples, runs into multi billions of US dollars.

"We think there's at least 500,000 researchers and at least 80,000 labs that can use of our system," he told the SNNLive video interview.

WATCH IT HERE...

"Right now we are in about 165 labs of the 80,000. We are a small company. We've had one salesperson for the last nine years. We've had minimal money to develop things. We had one instrument that was run by a microprocessor. Things have really changed for us in the last year."

Schumacher explained how the group now had six salespeople, with four new instruments that are ready to come out on top of the one it already had.

"We now have a brand new instrument that is computer driven, not run by a microprocessor, has tremendous software."

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

Last week, Pressure said it was to collaborate with Phasex Corporation to combine its ultra shear technology with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

Pressure Biosciences's Schumacher has also conducted an interview with NetworkNewsWire (NNW), a financial news and publishing company.

WATCH IT HERE.

"We supply instruments and consumables to life science laboratories all over the world," says Schumacher.

"These are the laboratories that are aggressively looking for the next billion-dollar drug, the next cure, the next preventive strategy, the next vaccine."

]]>
Wed, 25 Oct 2017 16:22:00 -0400 http://www.proactiveinvestors.com/companies/news/186218/pressure-biosciences-schumacher-upbeat-on-market-potential-for-its-life-science-tools-186218.html
<![CDATA[News - Pressure BioSciences hires NetworkNewsWire for corporate communications ]]> http://www.proactiveinvestors.com/companies/news/186038/pressure-biosciences-hires-networknewswire-for-corporate-communications-186038.html Pressure BioSciences Inc (OTCQB: PBIO), the technology and sample market specialist, revealed it had hired corporate communications firm NetworkNewsWire (NNW).

"Our award-winning proprietary technology is being installed in some of the top research laboratories around the world, we have just gone from one to six sales personnel, we will finish the development and release four new instruments to the market over the next 18 months, and our revenue continues to grow year-over-year," said Richard T. Schumacher, president and chief executive in a regulatory statement.

"We look forward to integrating NetworkNewsWire's strategies into our own as we focus on delivering an equitable return to our shareholders by increasing the exposure of our company and its potentially remarkable impact on the life sciences industry."

NNW is a financial news and publishing company, it said.

Its strategies help public and private organizations find their voice and build market visibility.

"Pressure BioSciences has developed a cutting-edge technology that has the potential to play a significant role in a number of commercially important areas," states Sherri Franklin, director of Content Marketing for NNW.

Last week it emerged that Pressure BioSciences was  to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

The UST technology has recently been issued its first two patents in China.

Shares added 3.24% to US$4.14 each

]]>
Mon, 23 Oct 2017 09:02:00 -0400 http://www.proactiveinvestors.com/companies/news/186038/pressure-biosciences-hires-networknewswire-for-corporate-communications-186038.html
<![CDATA[News - Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech ]]> http://www.proactiveinvestors.com/companies/news/185825/pressure-biosciences-has-high-hopes-for-phasex-corporation-collaboration-on-ust-tech-185825.html Pressure BioSciences Inc (OTCMKTS:PBIO) is to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

As reported earlier this month, the UST technology was recently issued its first two patents in China.

"Following discussions with our colleagues at PBI, we believe the UST platform can be scaled to a cost-effective, commercially-viable level," Hans Schonemann, the president of Phasex, one of the world's most experienced supercritical fluid (SCF)-based toll processors.

"This would allow production of large quantities of stable, water-soluble nanoemulsions of compounds that were previously water-insoluble, such as CBD from cannabis.

"Such aqueous nanoemulsions could significantly increase the absorption and bioavailability of CBD and other previously water-insoluble compounds, which we believe would subsequently result in significant increases in their commercial demand."

Richard Schumacher, the chief executive and president at Pressure BioSciences, added: "We believe the ability to subject liquids to UST following the Phasex SCF extraction and purification process would be a highly sought-after "Value-add" for Phasex customers.

"Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies.

"Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration."

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch).

]]>
Wed, 18 Oct 2017 11:20:00 -0400 http://www.proactiveinvestors.com/companies/news/185825/pressure-biosciences-has-high-hopes-for-phasex-corporation-collaboration-on-ust-tech-185825.html
<![CDATA[News - Pressure BioSciences' latest Barocycler machine's credentials featured at scientific meetings ]]> http://www.proactiveinvestors.com/companies/news/185364/pressure-biosciences-latest-barocycler-machine-s-credentials-featured-at-scientific-meetings-185364.html Pressure cycling technology (PCT) specialist Pressure BioSciences Inc (OTCMKTS:PBIO) says its recently released Barocycler 2320EXTREME instrument has received plaudits at several European scientific meetings - boosting its potential in the European biopharma markets.

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.

It is estimated that there are over 1bn FFPE (formalin-fixed, paraffin-embedded) tissue samples in the world, collected over a span of many decades," says Dr Nathan Lawrence, the vice president of marketing and sales at Pressure BioSciences.

"Complete clinical histories for such samples are often available, including such important data as disease progression and outcome, medications taken, and symptoms.

"More effective analyses of such samples, enabled by methods such as PCT, is expected to result in a bonanza of new and important biomarker discoveries. These discoveries open pivotal opportunities for development of new drugs, therapies, and disease-prevention strategies."

SCIEX, the co-marketing partner of PBI, organized an all-day seminar focused on the latest applications of mass spectrometry in digital biobanking in Munich, which discussed the Barocycler 2320EXT.

The 55th European High Pressure Research Group  took place in Poznan, Poland and looked at high pressure research.

The 16th Human Proteome Organization (HUPO) World Congress took place in Dublin, Ireland.

The OTCQB-listed firm develops and sells proprietary laboratory instrumentation and associated consumables to the US$6bn life sciences sample preparation market.

Shares added 3.24% to US$4.14 in New York.

]]>
Tue, 10 Oct 2017 12:09:00 -0400 http://www.proactiveinvestors.com/companies/news/185364/pressure-biosciences-latest-barocycler-machine-s-credentials-featured-at-scientific-meetings-185364.html
<![CDATA[News - Pressure BioSciences' chief upbeat on company's potential despite recent stock lows ]]> http://www.proactiveinvestors.com/companies/news/185360/pressure-biosciences-chief-upbeat-on-company-s-potential-despite-recent-stock-lows-185360.html Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher is upbeat on the instrument developer's potential and says it has transformed from where it was nine years ago.

The chief executive recently conducted a podcast on the Uptick Network Stock Day, where he spoke about the firm's growing sales and its sales teams.

WATCH THE PODCAST HERE..

From having just one salesperson previously, he told presenter Everett Jolly: "We now have six sales people, we have a brand new award-winning instrument that is opening up doors and areas of biopharma companies, that we could never have got into before."

Last month the group revealed its  next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME -  had been selected as a finalist in the prestigious R&D 100 Awards for 2017.

"This company is at an all time high in its potential and its ability to succeed and bring back a great return on investment for investors, and yet we've been hitting our all-time lows in the  past month as a stock price," explained Schumacher.

"Our sales are increasing and our stock price is really not responding."

"We've already broken US$1mln in the first half of the year. In the third quarter, I've already given guidance that investors should expect a record number for our third quarter. Things aren't going down, things are actually moving up.." he added.

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

The group is a pressure expert and UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch)

 "The company believes that UST has the potential to play a significant role in a number of commercially important areas, including the formulation of high quality stable nanoemulsions and the preparation of extended shelf-life "clean label" food," it told investors.

Shares in New York added 3.24% on the day to US$4.14 each.

]]>
Tue, 10 Oct 2017 10:49:00 -0400 http://www.proactiveinvestors.com/companies/news/185360/pressure-biosciences-chief-upbeat-on-company-s-potential-despite-recent-stock-lows-185360.html
<![CDATA[News - Pressure BioSciences reveals UItra Shear Technology patent news ]]> http://www.proactiveinvestors.com/companies/news/184935/pressure-biosciences-reveals-uitra-shear-technology-patent-news-184935.html Pressure BioSciences Inc (OTCMKTS:PBIO) is excited at the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

READ - Pressure BioSciences' Barocycler instrument named finalist in 2017 R&D 100 awards READ THE BIG PIC - Pressure BioSciences' technology is building momentum

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch)

"The company believes that UST has the potential to play a significant role in a number of commercially important areas, including the formulation of high quality stable nanoemulsions and the preparation of extended shelf-life "clean label" food," it told investors today.

One use is to make what's called nanoemulsions - mixtures of two or more liquids, which could be used in various medical products, pharmaceuticals, nutraceuticals, and cosmetics.

"Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels, and other advantages can be achieved with nanoemulsions when compared to standard macro- and micro-emulsions," the firm said.

Meanwhile, a number of clean label foods are currently processed using high-pressure treatments, including many juices, seafood, meats and fruits and vegetables.

In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at US$10 billion.

Dr Edmund Y. Ting, from Pressure BioSciences, who is a pioneer in the development of HPP and a co-inventor of UST, said: "HPP is very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives."

He added: "UST uses ultra-high pressures to generate intense shear forces under controlled temperature conditions to produce nanoemulsions with significant reductions in food-borne pathogens, perhaps reaching sterilization. Evidence suggests that under such extreme conditions, even bacterial spores can be inactivated."

He said Pressure's initial focus will be to evaluate UST for the production of high-quality dairy products and beverages.

Shares eased 4.29% to US$4.02 each.

]]>
Mon, 02 Oct 2017 11:39:00 -0400 http://www.proactiveinvestors.com/companies/news/184935/pressure-biosciences-reveals-uitra-shear-technology-patent-news-184935.html
<![CDATA[News - Pressure Biosciences' Barocycler instrument named finalist in 2017 R&D 100 awards ]]> http://www.proactiveinvestors.com/companies/news/184162/pressure-biosciences-barocycler-instrument-named-finalist-in-2017-rd-100-awards-184162.html Pressure Biosciences Inc (OTCQB: PBIO), the life sciences sector sample preparation firm, said its  next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME -  was selected as a finalist in the prestigious R&D 100 Awards for 2017.

Finalists were chosen by an independent panel of more than 50 judges, based on each product's impact potential, uniqueness, and technical capabilities, said the firm.

This year's winners will be announced at a ceremony on November 17 this year.

ProCan, a cancer research initiative in Australia and the first international collaborator of the US Cancer Moonshot program, purchased three of the products last year

Professor Phil Robinson, co-director, said: "We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. The goal is to diagnose each individual patients' cancer to make more rapid and accurate predictions of the best cancer treatment to use -- or to avoid -- for that individual. This will also advance scientific discovery for new drug targets."

He added: "Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, a project like ProCan simply could not be done."

Shares added 3.24% to US$4.14

]]>
Mon, 18 Sep 2017 13:19:00 -0400 http://www.proactiveinvestors.com/companies/news/184162/pressure-biosciences-barocycler-instrument-named-finalist-in-2017-rd-100-awards-184162.html
<![CDATA[News - Pressure Biosciences eyes further revenue growth for 2017 after second quarter numbers ]]> http://www.proactiveinvestors.com/companies/news/182554/pressure-biosciences-eyes-further-revenue-growth-for-2017-after-second-quarter-numbers-182554.html Pressure Biosciences Inc (OTCMKTS:PBIO) continues to see quarter-on-quarter growth in total revenue, products and services revenue, and instrument sales, the firm said in its second quarter results.

However, the operating loss was widened in the three months to end June to $1.204mln from $1.060mon in the same period last year - an increase of 14% - largely due to increased sales and marketing expenses.

READ THE BIG PICTURE HERE - Pressure Biosciences' technology is building momentum READ - Pressure Biosciences delighted at collaborator's recognition

The company develops and sells proprietary laboratory instrumentation and associated consumables to the sample preparation market.

In April this year. Joseph L. Damasio joined the company as its chief financial officer. He said the second quarter had seen progress in several important areas.

Specifically, the firm, he said,  worked closely with contract manufacturer and raw materials vendors in an effort to reduce the costs of both the parts and assembly of our recently released, next generation Barocycler 2320EXTREME instrument.

The company also upgraded the systems and procedures used to analyze and track inventory, bill-of-materials, and costs-of-goods-sold.

Richard T. Schumacher, President and chief executive, added that it had hired a five-member field sales force.

"We expect all five sales directors to be fully trained and in the field between Labor Day and the end of September 2017," he said, expecting them to impact sales from the third quarter.

"...we made measurable progress on our goal to upgrade the software on our Barocycler 2320EXT to GMP/GLP-compliance, which we believe will open up a significant market opportunity for the 2320EXT in the drug design, development, validation, manufacture, and quality control of biological drugs...," he added

"....we announced for the first time that we have filed a patent for 'ultra-shear technology,' which we believe could address a significant, unmet need in both the biopharma and 'clean label' food areas."

Total revenue in the second quarter was $540,372 compared to $510,963 during the same period in 2016, an increase of 6%, mainly due to higher revenue from grant related activities and instrument sales.

Products and services revenue increased to $480,400, compared to $474,187 last year - an increase of 1%.

Net loss in the quarter was $583,760, compared to an income of $961,829 in the same period of 2016.

]]>
Wed, 16 Aug 2017 14:54:00 -0400 http://www.proactiveinvestors.com/companies/news/182554/pressure-biosciences-eyes-further-revenue-growth-for-2017-after-second-quarter-numbers-182554.html
<![CDATA[News - Pressure Biosciences delighted at collaborator's recognition ]]> http://www.proactiveinvestors.com/companies/news/178795/pressure-biosciences-delighted-at-collaborator-s-recognition-178795.html Pressure Biosciences Inc (OTCMKTS:PBIO), the lab instrumenation specialist, said collaborator Dr Ruedi Aebersold, has been recognised in a prestigious bioanalytics award scheme.

Aebersold received the Karger Medal from the Barnett Institute of Chemical & Biological Analysis in Boston, Masachusetts.

It recognizes an individual who has 'significantly contributed' to the development of new bioanalytical methods.

As part of the ceremony, Dr Aebersold presented two seminars, which highlighted his research in proteomics - the study of the entire set of proteins produced by healthy and diseased cells.

Both lectures included slides describing his use of Pressure BioSciences' novel, award winning, next-generation Barocycler 2320EXTREME for proteomic sample preparation in biomarker discovery and other research applications.

Quoting from the lectures, the firm said the doctor explained: "Not only do we need to consider the method of analyzing the proteome, we must also recognize that the method of sample preparation used for extraction and digestion of proteins is equally important to achieve a high degree of reproducibility of research results."

In 2015, Dr Aebersold and Dr Tiannan Guo collaborated with Pressure scientists and engineers to develop PCT-SWATH, a sample preparation and analysis method that combines the firm's sample preparation platform with SCIEX's SWATH-MS-based proteomics workflow.

PCT-SWATH is also notably employed by ProCan, a cancer research initiative at the Children's Medical Research Institute in Australia, which is also an NCI Cancer Moonshot collaborator.

Vice president of marketing and sales at Pressure BioSciences Dr Nate Lawrence, said: "We are delighted that Dr. Aebersold has again been recognized for his groundbreaking research in proteomics.

"We are honored to be both his colleague and collaborator in the development of instrumentation and methods essential in the preparation of samples for the discovery of protein biomarkers and other important applications.

"We look forward to working with Professor Aebersold and his team for years to come."

Shares in New York rose almost 6% to $6.99 each.

]]>
Mon, 05 Jun 2017 11:55:00 -0400 http://www.proactiveinvestors.com/companies/news/178795/pressure-biosciences-delighted-at-collaborator-s-recognition-178795.html
<![CDATA[News - Pressure BioSciences announces 1-for-30 stock consolidation ]]> http://www.proactiveinvestors.com/companies/news/178731/pressure-biosciences-announces-1-for-30-stock-consolidation-178731.html Pressure Biosciences Inc. ( OTCMKTS:PBIO ) has announced a one-for-thirty reverse split of its common stock to take effect next Monday.

The shares underlying the company's outstanding convertible securities will also be adjusted accordingly, the laboratory instruments designer told investors.

The reverse split will have the effect of reducing the number of shares each shareholder owns while at the same time increasing the value of each share, effectively leaving the value of each shareholder’s stake unchanged.

Once the reverse split - also known as a consolidation - has taken place, there will be around 1.06mln Pressure Bio shares in issue.

]]>
Fri, 02 Jun 2017 13:02:00 -0400 http://www.proactiveinvestors.com/companies/news/178731/pressure-biosciences-announces-1-for-30-stock-consolidation-178731.html
<![CDATA[News - Pressure Biosciences' solid growth expected to continue, says SeeThruEquity ]]> http://www.proactiveinvestors.com/companies/news/178274/pressure-biosciences-solid-growth-expected-to-continue-says-seethruequity-178274.html Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences Inc (OTCMKTS:PBIO) following its first quarter results.

The medtech and life sciences group began 2017 with nice growth, with revenues up 8% at $551,357 year-on-year, it said.

Business was particularly strong in the company's products and services segment, which demonstrated 16% annual growth led by strong instrument sales, noted SeeThruEquity.

"On its call with investors, PBIO management stated that it expected sales growth throughout the year as it expands distribution and selling partnerships, including the recently announced partnership with EKG Sales Associates; the company also expects an increase in grant revenues later in the year," it added.

A CE mark for Barocycler...

The research group also said that the firm had achieved its CE marking for its Barocycler 2320EXTREME sample instrument system faster than originally expected.

"The CE Marking is a significant milestone as it allows the Barocycler to be sold in Europe," it said.

"The company has announced that it is pursuing an uplisting to the Nasdaq, with a goal of completing the process by the end of 2Q17.

"We expect this move will require a transaction that will bring in much needed capital, but also affect shares outstanding, in order to meet minimum share price and shareholder's equity thresholds for a national listing," it added.

Last week, Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss."

]]>
Wed, 24 May 2017 10:41:00 -0400 http://www.proactiveinvestors.com/companies/news/178274/pressure-biosciences-solid-growth-expected-to-continue-says-seethruequity-178274.html
<![CDATA[News - Pressure Biosciences increases revenue and gross margins in first quarter ]]> http://www.proactiveinvestors.com/companies/news/177875/pressure-biosciences-increases-revenue-and-gross-margins-in-first-quarter-177875.html Sales of products and services helped boost revenues in the first quarter, said Pressure Biosciences Inc (OTCMKTS:BIO), positioning it well for growth in the rest of fiscal 2017.

The life sciences group develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market

READ - Pressure Biosciences names Damasio as finance chief as it travels towards profitability READ BIG PICTURE - Pressure Biosciences' technology is building momentum

Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite a decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss.

"We believe the financial results of the first quarter 2017 have set us up well to significantly drive revenue and business growth for the rest of the fiscal 2017 year, and beyond."

Richard T. Schumacher, president and chief executive, added: "Although pleased with the financial results of the first quarter, we are even more pleased with our operational accomplishments."

Included in these, in February, it achieved CE Marking for its Barocycler 2320EXT, the next-generation PCT-based sample preparation instrument.

Pressure can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

Shares lost 5.82% on the day.. 

]]>
Tue, 16 May 2017 13:22:00 -0400 http://www.proactiveinvestors.com/companies/news/177875/pressure-biosciences-increases-revenue-and-gross-margins-in-first-quarter-177875.html
<![CDATA[News - Pressure Biosciences names Damasio as finance chief as it travels towards profitability ]]> http://www.proactiveinvestors.com/companies/news/176472/pressure-biosciences-names-damasio-as-finance-chief-as-it-travels-towards-profitability-176472.html Pressure Biosciences Inc (OTCQB:PBIO) has welcomed Joseph L Damasio back to the company as it ramps up, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

READ - Pressure Biosciences' technology is building momentum READ - Pressure BioSciences sets stage for "very successful" 2017

Most recently, the experienced executive was finance director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over $100mln in annual global sales.

Damasio told investors on Monday: "The company has developed and is beginning to implement a comprehensive fiscal plan that we believe is both achievable and sustainable, while supporting continued growth.

"Among its many goals, the plan calls for an up-list to the NASDAQ stock market, the addition of personnel in key areas, a strong focus in and expansion of sales and marketing, and a march towards profitability."

Pressure's president and chief executive Richard T. Schumacher added : "We are delighted to have Joe re-join the senior management team at PBI.

"During his five years away, Joe gained a wealth of knowledge and experience that we believe will help us significantly as we look to accelerate the company's growth on our path to profitability and long-term success. Welcome back, Joe."

Last month, the group bolstered its marketing and sales capabilities by contracting a well-regarded life sciences lead generation service and hiring two of four new field sales directors.

EKG Sales Associates (EKG) has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers.

As well as engaging EKG, PBI has also hired Ms Rajni Kareer who will be the sales director covering all of the west coast of the US.

The other new director, Nicholas Cobb, will cover upstate New York, northern New England, and all of eastern Canada.

Shares shed over 4% to US$0.31.

]]>
Mon, 17 Apr 2017 10:04:00 -0400 http://www.proactiveinvestors.com/companies/news/176472/pressure-biosciences-names-damasio-as-finance-chief-as-it-travels-towards-profitability-176472.html
<![CDATA[News - Pressure BioSciences expands sales capabilities with new hires ]]> http://www.proactiveinvestors.com/companies/news/175312/pressure-biosciences-expands-sales-capabilities-with-new-hires-175312.html Pressure Biosciences Inc  (OTCQB:PBIO) has bolstered its marketing and sales capabilities for 2017 by contracting a well-regarded life sciences lead generation service and hiring two of four new field sales directors.

EKG Sales Associates (EKG) has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers.

As well as engaging EKG, PBI has also hired Ms Rajni Kareer who will be the sales director covering all of the west coast of the US.

The other new director, Nicholas Cobb, will cover upstate New York, northern New England, and all of eastern Canada.

He will also have responsibility for field service throughout the US and Canada.

Both hires have a strong background in selling capital equipment to research laboratories, including spectrometers and HPLC equipment, as well as lab consumables.

Roxana McCloskey, director of marketing and sales for North America, said: "We are excited with the hires of EKG and our two new field sales directors, but there is still much to do to complete our plan to build a viable, experienced, and successful marketing and sales team at PBI.

"We are committed to the immediate hire of at least two additional field sales directors, one each for the mid-west and east coast regions."

Yesterday, the firm revealed that the growth in products and services sales helped it to post a 10% increase in revenue in the year just gone.

Total revenue for the year to end December came in at $1.97mln compared to $1.79 mln in the same period of 2015.

Products and services revenue was up 27% to $1.79mln in 2016 versus $1.409mln in 2015.

]]>
Thu, 23 Mar 2017 13:06:00 -0400 http://www.proactiveinvestors.com/companies/news/175312/pressure-biosciences-expands-sales-capabilities-with-new-hires-175312.html
<![CDATA[News - Pressure BioSciences sets stage for "very successful" 2017 ]]> http://www.proactiveinvestors.com/companies/news/175244/pressure-biosciences-sets-stage-for-very-successful-2017-175244.html Growth in products and services sales helped Pressure Biosciences Inc (OTCQB: PBIO) post a 10% increase in revenue in the year just gone.

Total revenue for the year to end December came in at $1.97mln compared to $1.79 mln in the same period of 2015.

Products and services revenue was up 27% to $1.79mln in 2016 versus $1.409mln in 2015.

The operating loss was $3.73mln compared to a loss of $3.56mln in 2015, due primarily to increases in R&D, Sales and Marketing, and IR expenses, off-set to a certain extent by an increase in Total revenue.

Pressure Biosciences Inc had a busy 2016 in which it made progress, it said. The biotech is developing and selling laboratory instrumentats and associated consumables to the estimated $6bn life sciences sample preparation market.

Last month, it achieved CE Marking for its sample preparation instrument  Barocycler 2320EXTREME, giving it the green light to sell the product in Europe.

President and chief executive Richard T. Schumacher said: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017."

The group enters the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; a larger customer base; and enhanced sales and marketing capability, he said.

The 2017 goals include:  an up-list to the NASDAQ stock market in the second quarter,  measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity,  continuing  sales and marketing capabilities, and reach into new countries, investigators, and fields-of-use; and a focus on sales.

Shares added 6% to 27 cents.

]]>
Wed, 22 Mar 2017 14:15:00 -0400 http://www.proactiveinvestors.com/companies/news/175244/pressure-biosciences-sets-stage-for-very-successful-2017-175244.html
<![CDATA[News - Pressure BioSciences hits the CE Mark with next-gen sample preparation instrument ]]> http://www.proactiveinvestors.com/companies/news/172582/pressure-biosciences-hits-the-ce-mark-with-next-gen-sample-preparation-instrument-172582.html Pressure BioSciences, Inc. (OTCQB: PBIO) shares advanced by 6% on Thursday after the company said it had achieved CE Marking for the Barocycler 2320EXTREME, the company's recently-released, next-generation PCT-based sample preparation instrument, and has the green light to sell in Europe.

A leader in the development and sale of broadly enabling, pressure cycling technology (PCT)-based sample preparation solutions to the worldwide life sciences industry, PBIO said the company is permitted to begin sales of the Barocycler 2320EXT in the European Economic Area.

Since 1985, achievement of CE Marking has been required for products in 24 different categories sold within the European Economic Area. Each product falls under one or more Directives, which determine the specific requirements the product must meet.

When the CE Mark is affixed to a product, it signifies the manufacturer's declaration that the product meets all applicable EU safety, health, or environmental requirements. Achieving CE Marking requires substantial cost, time, and effort from the manufacturer, but allows the product to be marketed and move freely throughout all 31 countries in the EEA that require the CE Mark.

The Barocycler 2320EXT is the most recent addition to, and the next generation of, PBI's Barocycler family. It is a compact, bench top instrument offering many features and benefits not found in PBI's earlier Barocycler models, such as data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These and other features have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders (KOLs) worldwide, when preparing protein samples for analysis.

Among these KOLs is Professor Ruedi Aebersold, a world-renowned protein chemist and Director of the Institute of Molecular Systems Biology in Zurich, Switzerland. Professor Aebersold has been a leading proponent of PBI's PCT-based sample preparation methods prior to proteomic analyses for some time.

"Achievement of CE Marking for the Barocycler 2320EXT is an important next step in our commercialization plans for this powerful and enabling sample preparation instrument, especially since CE Marking is required prior to selling the Barocycler 2320EXT to the large and potentially lucrative biopharmaceutical market in Europe,” said Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI

“We recently signed agreements with several strong distribution partners in Europe, our SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe), and Professor Ruedi Aebersold - one of the most recognized world leaders in proteomics - recently purchased two Barocycler 2320EXTs. We believe we are well prepared for our upcoming, planned launch of the CE Marked Barocycler 2320EXT in Europe. These are very exciting times for PBI."

BPIO shares were up 6.1% at $0.16 on Thursday.

]]>
Thu, 02 Feb 2017 12:58:00 -0500 http://www.proactiveinvestors.com/companies/news/172582/pressure-biosciences-hits-the-ce-mark-with-next-gen-sample-preparation-instrument-172582.html
<![CDATA[News - Pressure BioSciences to present at RedChip's Global Online Growth Conference ]]> http://www.proactiveinvestors.com/companies/news/172134/pressure-biosciences-to-present-at-redchip-s-global-online-growth-conference-172134.html Pressure Biosciences Inc (OTCMKTS:BIO) said on Tuesday Richard T. Schumacher, President and CEO, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday January 25, 2017, at 11:30am EST.

The company is a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry.

]]>
Tue, 24 Jan 2017 15:10:00 -0500 http://www.proactiveinvestors.com/companies/news/172134/pressure-biosciences-to-present-at-redchip-s-global-online-growth-conference-172134.html
<![CDATA[News - Pressure BioSciences to present at the 2017 Biotech Showcase ]]> http://www.proactiveinvestors.com/companies/news/171423/pressure-biosciences-to-present-at-the-2017-biotech-showcase-171423.html Pressure Biosciences Inc (OTCMKTS:BIO) said on Tuesday Richard T. Schumacher, President and CEO, will present a corporate overview at the 9th Annual Biotech Showcase at 1700 PST later today.

The Biotech Showcase is being held January 9-11 at the Hilton San Francisco Union Square, San Francisco, CA.

Pressure Biosciences is a leader in the development and sale of broadly enabling, pressure cycling technology-based sample preparation solutions to the worldwide life sciences industry.

Pressure Biosciences Inc shares were up 2.6% at $0.18 on Tuesday.

]]>
Tue, 10 Jan 2017 13:54:00 -0500 http://www.proactiveinvestors.com/companies/news/171423/pressure-biosciences-to-present-at-the-2017-biotech-showcase-171423.html
<![CDATA[News - Pressure Biosciences' technology is building momentum ]]> http://www.proactiveinvestors.com/companies/news/171264/pressure-biosciences-technology-is-building-momentum-171264.html Pressure Biosciences Inc (OTCMKTS:BIO) has seen momentum building behind its proprietary technology  and it is primed for a successful fiscal 2017.

Revenues are on the rise and the group’s efforts to bring in new business is delivering.

The firm develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market.

The company got a major shot in the arm in December and now sees itself playing a key role in a new cancer research initiative in the United States, following the introduction of new legislation.

First quarter shows financial and operational success

Sales of products and services helped boost revenues in the first quarter. Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite the decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

A CE mark for preparation instrument

In February this year, it achieved a CE Marking for its sample preparation instrument  Barocycler 2320EXTREME, giving it the green light to sell the product in Europe.

It can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

And it has now welcomed back veteran financial executive Joseph L Damasio back to the company, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

A major role in a cancer moonshot

In December, 2016, the company told investors that it expects to play a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed.

Specifically, it is set to benefit from the 21st Century Cures Act which included $1.8bn earmarked specifically for cancer research.

Pressure BioSciences’ technology is already being featured as an essential technology and used by leading researchers participating in the ‘Cancer Moonshot’ and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete.

This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st Century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

Proprietary technology and winning over opinion leaders

Pressure Biosciences’ proprietary PCT-HD system has in recent years been trialled and adopted by leading scientists.

“We have a unique, patented technology that is now beginning to be appreciated by scientists around the world,” Richard Schumacher, the group’s founder and chief executive said earlier this year.

Schumacher highlighted that generally the life sciences have moved on significantly in past decades with the focus increasingly upon the intricacies within cells rather than what occurs around the outsides of them.

However, he says the technological approach to actually ‘open’ cells remains relatively crude and are still largely the same as they were in the 1980s (when he was last in the lab in a scientific capacity).

At Pressure BioSciences we’ve developed this new method, never been used before, to open the cell and get “all the good stuff” out.

“Essentially it is like a sponge, we squeeze it out. Where others beat up ‘the sponge’ using mechanical, we put it in a pressure chamber. It is much gentler, it is much more controllable.”

Schumacher points out that, generally speaking, scientists are stubborn people by nature,  and convincing them to change their working practices has been one of the biggest challenges for the company.

But, by targeting what he calls ‘key opinion leaders’ in certain specialist fields Schumacher says Pressure Bioscience has started to overcome this hurdle.

“You have to go after the key opinion leaders. The scientists around the world that are recognised as the experts in studying proteins, DNA, RNA and lipids.

“We have to go after them and get them to use the technology with the assumption that once they’ve used it, they’ll realise how much better the system is. That’s what we’ve done."

]]>
Fri, 06 Jan 2017 08:36:00 -0500 http://www.proactiveinvestors.com/companies/news/171264/pressure-biosciences-technology-is-building-momentum-171264.html
<![CDATA[News - Pressure BioSciences,’ big role in $1.8bn "Cancer Moonshot" initiative ]]> http://www.proactiveinvestors.com/companies/news/170622/pressure-biosciences-big-role-in-18bn-cancer-moonshot-initiative-170622.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) sees itself playing a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed this week, according to a statement on Friday.

A leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, the company discussed the potential impact of the $6.3bn 21st Century Cures Act that was signed into law earlier this week.

The bill contains $1.8bn earmarked specifically for cancer research – the so-called Cancer Moonshot initiative.

The Company's PCT sample preparation system is already being featured as an essential technology and used by leading researchers participating in the Cancer Moonshot and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete. This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

"We believe strongly that discovery starts with sample preparation. Consequently, it is critical that cancer researchers have access to cutting-edge instruments, consumables, and other products that will give them the best chance of success, by giving them the best-in-class method or methods to prepare their samples prior to testing," said Dr. Nate Lawrence, Vice President of Marketing and Sales at PBI.

"We believe that, in many cases, the use of our PCT Sample Preparation System in protein analysis results in higher quality research data when compared to sample preparation with current technologies. This should result in a greater opportunity for discovery, which is one of the most important goals of the Cancer Moonshot initiative," he added.

The developments come just a month after the company reported bullish third quarter earnings. Read more.

]]>
Fri, 16 Dec 2016 14:18:00 -0500 http://www.proactiveinvestors.com/companies/news/170622/pressure-biosciences-big-role-in-18bn-cancer-moonshot-initiative-170622.html
<![CDATA[News - Pressure BioSciences hits record high quarterly product revenues ]]> http://www.proactiveinvestors.com/companies/news/169096/pressure-biosciences-hits-record-high-quarterly-product-revenues-169096.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) product and services revenues picked up in the third quarter to a record high and touched above $500,000 for the first time in any quarter - while lower expenses helped lead to a lower operating loss, the company said on Wednesday.

In the three months ended Sept 30, revenue from products and services amounted to $500,949 compared with $481,452 in the same period of 2015.

This was a record high for products and services revenue in a quarter and marked the first time that products and services revenue exceeded half a million dollars in a financial quarter.

Revenue was driven primarily by the sale of instruments, which also set a record high with $383,789 for the quarter, compared to $340,084 (the previous record) for the same quarter of 2015.

“We expect grant revenue to begin to increase in the fourth quarter of 2016 and continue to increase into 2017. Total revenue decreased to $535,334 in the third quarter 2016 from $580,334 for the third quarter of 2015. This decrease was due to the decrease in grant revenue,” the company said in a statement.

Total operating costs and expenses fell to $987,141 versus $1.271mln a year earlier. The operating loss incurred was substantially down at $451,807 compared with $690,728 a year earlier.

“Although we continue to carefully control expenditures, this decrease in operating loss was primarily due to credits received from a professional service organization the Company no longer uses,” it said in the statement.

“We believe that had these credits not been received, operating loss for Q3 2016 would have been greater than the operating loss for Q3 2015, primarily because of discounts we offered to initial purchasers of our new next-generation Barocycler 2320EXTREME instrument, higher costs experienced in sales and marketing as we began to expand such capabilities, and costs associated with pursuing CE Marking for the new Barocycler 23230EXTREME. A CE Mark is required by dozens of countries in order to sell product in their country.”

]]>
Wed, 16 Nov 2016 14:34:00 -0500 http://www.proactiveinvestors.com/companies/news/169096/pressure-biosciences-hits-record-high-quarterly-product-revenues-169096.html
<![CDATA[News - Pressure BioSciences makes initial close in $2.5mln funding ]]> http://www.proactiveinvestors.com/companies/news/168956/pressure-biosciences-makes-initial-close-in-25mln-funding-168956.html Pressure Biosciences Inc (OTCMKTS:PBIO) on Monday announced the initial close of $610,000 in gross proceeds in a $2.5 mln private placement.

A leader in the development and sale of broadly enabling, pressure-based sample preparation solutions to the worldwide life sciences industry, led by their patented pressure cycling technology platform, the company said that three accredited investors participated in the financing.

All investments were made in cash and were received into escrow between August 29 and November 10. One or more additional closes in the financing are expected to occur in the near future.

The company issued 1,525,000 shares of restricted common stock at $0.40 per share and common stock purchase warrants exercisable into a total of 1,525,000 shares of restricted common stock at $0.50 per share.

There are no registration rights with respect to the shares of common stock or the shares underlying the common stock purchase warrants issued. The company received net proceeds of $512,750 after subtracting legal and placement agent fees related to the financing.

]]>
Mon, 14 Nov 2016 14:49:00 -0500 http://www.proactiveinvestors.com/companies/news/168956/pressure-biosciences-makes-initial-close-in-25mln-funding-168956.html
<![CDATA[News - Pressure BioSciences, Inc. closes $2mln Line-of-Credit ]]> http://www.proactiveinvestors.com/companies/news/168505/pressure-biosciences-inc-closes-2mln-line-of-credit-168505.html Pressure Biosciences Inc (OTCMKTS:PBIO) shares rose on Thursday after the company said it has closed a $2 million line-of-credit with an accredited investor.

A leader in the development and sale of broadly enabling constant pressure and pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, Pressure Bio said the investor on Oct 28 bought a Promissory Note worth $2mln payable on the earlier of October 28, 2017 (the maturity date) or on the seventh business day after the closing of a Qualified Offering.

On the same day, the company received its initial $250,000 advance linked to the Note and issued to the Investor a five-year Common Stock Purchase Warrant to purchase 625,000 shares of the Company's common stock ("Common Stock") at an exercise price equal to $0.40 per share.

Pressure BioSciences shares closed up 2.3% at $0.29 on Thursday.

]]>
Thu, 03 Nov 2016 16:55:00 -0400 http://www.proactiveinvestors.com/companies/news/168505/pressure-biosciences-inc-closes-2mln-line-of-credit-168505.html
<![CDATA[News - Pressure BioSciences' PCT platform features at major Australian cancer research centre ]]> http://www.proactiveinvestors.com/companies/news/168101/pressure-biosciences-pct-platform-features-at-major-australian-cancer-research-centre-168101.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced on Wednesday its featured participation in the recent opening of The ACRF International Centre for the Proteome of Human Cancer ("ProCan"), located in newly renovated laboratory facilities at the Children's Medical Research Institute ("CMRI") near Sydney, Australia.

PBI, the leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, said that in addition to itself, ProCan and CMRI scientists, presentations were made by other invitees, including representatives from SCIEX, Ilumina, Beckman-Coulter, and NextBio, as well as from Dr. Tiannan Guo of Professor Ruedi Aebersold's lab at the world-renowned Institute of Molecular Systems Biology (Zurich, Switzerland).

Professor Aebersold is generally considered to be one of the leading proteomics scientists in the world.

ProCan expects to analyse a minimum of 10,000 cancer tumor samples per year over the next seven years with cutting-edge protein analysis instruments and other lab tools. It is anticipated that data from their studies will trigger discoveries illuminating causes of cancer, providing invaluable guidance on cancer treatment options and creating a new era in standard operating procedures applied in cancer testing laboratories worldwide.

"CMRI was recently named an official collaborator of the US National Cancer Institute's "Cancer Moonshot" initiative, whose goal is to accelerate what would normally take ten years of cancer research into completion in the next five years,” said Dr. Nate Lawrence, Vice President of Sales and Marketing for PBI.

“We believe that the Cancer Moonshot initiative will strategically support and accelerate the field of precision (personalized) medicine through studies such as those planned at CMRI, which could lead to better identification, diagnosis, treatment, and prevention of cancer. We are proud to be a part of this very important and inspiring program."

]]>
Wed, 26 Oct 2016 14:48:00 -0400 http://www.proactiveinvestors.com/companies/news/168101/pressure-biosciences-pct-platform-features-at-major-australian-cancer-research-centre-168101.html
<![CDATA[News - Pressure BioSciences CEO to present at New York conference ]]> http://www.proactiveinvestors.com/companies/news/167504/pressure-biosciences-ceo-to-present-at-new-york-conference-167504.html Pressure Biosciences Inc’s (OTCMKTS:PBIO) President and chief executive, Richard Schumacher, will present a corporate overview and business update at the SeeThruEquity Fall Microcap Investment Conference in New York City later on this morning.

Schumacher is due to take the stage at the Convene Grand Central at 11.30am ET to present to an audience of industry professionals and investors.

STE conferences are the “ultimate event” for publicly traded companies with a market cap of less than US$1bln, Pressure said.

Pressure Biosciences platform technology is called pressure cycling technology (PCT), which uses hydrostatic pressure to control bio-molecular interactions.

A full recording of today’s presentation will be available on Pressure’s website (www.pressurebiosciences.com).

]]>
Mon, 17 Oct 2016 08:28:00 -0400 http://www.proactiveinvestors.com/companies/news/167504/pressure-biosciences-ceo-to-present-at-new-york-conference-167504.html
<![CDATA[News - Pressure BioSciences strengthens in Q2, focuses on sales ]]> http://www.proactiveinvestors.com/companies/news/129393/pressure-biosciences-strengthens-in-q2-focuses-on-sales-129393.html Pressure BioSciences, Inc. (OTCQB:PBIO) shares rose more than 7% on Tuesday after the company published its second quarter earnings and offered a sales-oriented strategy for its outlook.

Products and services revenue jumped to $474,187 for the quarter ended June 30, increasing 42%, from $333,575 over the same period in 2015. Consumable sales rose 29%, to a record $72,773 from $56,513.

Meanwhile, the company assigned grant personnel mostly to develop the company’s Barocycler 2320EXTREME next-generation instrument system. Pressure BioSciences recently sold Barocycler instruments to a major cancer research center recognized by the White House for its innovative work. The company also assigned grant personnel to additional sales and marketing activities.

Those activities helped partly explain a 24% jump in increased revenue, to over $510,000 in the second quarter. Meanwhile, the company also managed to improve its financial situation overall.

Pressure BioSciences President and CEO Richard Schumacher explained that the company had achieved all of the goals it set.

"Over the past year, our efforts have been primarily focused on strengthening and securing our financial future by eliminating all floorless debt, finding a co-marketing partner who is a global leader in the life sciences, particularly in the field of proteomics, designing then developing the next-generation Barocycler to support the co-marketing and other programs, developing the next-generation consumable products and applications for the PCT platform, and continuing to increase sales of our instrument systems and associated consumables.”

Now the company can start building traction.

"With key opinion leaders now as customers, with global life sciences leader SCIEX as our co-marketing partner, with the new higher-throughput computerized Barocycler 2320EXTREME built and ready for prime-time, and with the PBI Management Team now in place for over 10 years, it is time to turn our main focus from building infrastructure to building a robust and highly effective sales and marketing program,” Schumacher added.

Moving forward, the company is looking to expand sales and marketing initiatives, increase products and services, bring in more grant revenue and improve gross margins and ultimately, work towards an up-list to NASDAQ or the NYSE by the end of 2016.

Despite the more positive outlook overall, the company did note an operating loss for the quarter of over $1mln, with a related loss of net income per common share of $0.04 for basic shares. The loss came from substantial R&D costs from projects such as getting their Barocycler product to integrate with the company’s new ISO-certified contract manufacturer.

Pressure Biosciences shares closed up 7.5%, at $0.43 on Tuesday.

]]>
Tue, 16 Aug 2016 15:28:00 -0400 http://www.proactiveinvestors.com/companies/news/129393/pressure-biosciences-strengthens-in-q2-focuses-on-sales-129393.html
<![CDATA[News - Pressure BioSciences announces initial shipments of its next-generation PCT System ]]> http://www.proactiveinvestors.com/companies/news/128491/pressure-biosciences-announces-initial-shipments-of-its-next-generation-pct-system-128491.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced the initial shipments of its recently released, next-generation pressure cycling technology ("PCT")-based instrument, the Barocycler 2320EXTREME on Thursday. 

Five instruments were recently purchased and delivered: one to an Ivy-league school with a rich history in life sciences research, one to the company's exclusive distributor in China, and the remaining three to the Children's Medical Research Institute ("CMRI") near Sydney Australia.

The instruments purchased by CMRI will be used in cancer research studies by the newly established Australian Cancer Research Foundation International Centre for the Proteome of Cancer ("ProCan"), located in the CMRI facility.

ProCan has announced plans to analyse approximately 70,000 cancer tumor samples over the next seven years with state-of-the-art protein profiling instruments and other tools. Data from their studies are expected to enable discoveries around the causes of cancer, provide guidance on cancer treatment options, and generate standard operating procedures that can be used in cancer testing laboratories worldwide.

In their studies, ProCan will combine PBI's new Barocycler 2320EXT system for sample preparation with SCIEX's SWATH data independent-acquisition mass spectrometry workflow on Triple TOF 6600 Systems.  SCIEX is a global leader in life science analytical technologies. 

In January 2016, PBI and SCIEX announced an exclusive, two-year, worldwide co-marketing agreement under which PBI and SCIEX will co-promote PBI's PCT systems with SCIEX's SWATH-based proteomics workflows.

In his 2016 State-of-the-Union message, President Barack Obama introduced the $1bn 'Cancer Moonshot' initiative, with a goal to accelerate research in cancer, to break down existing barriers that stymie progress, and to support other changes that will improve the ability to prevent, detect, treat, and cure cancer. Vice-President Biden was asked to lead this effort.

On July 16, the White House named ProCan as one of four preeminent cancer centers in Australia chosen to collaborate with the US National Cancer Institute in the "Cancer Moonshot" initiative.

]]>
Thu, 21 Jul 2016 14:52:00 -0400 http://www.proactiveinvestors.com/companies/news/128491/pressure-biosciences-announces-initial-shipments-of-its-next-generation-pct-system-128491.html
<![CDATA[News - Pressure BioSciences unveils Barocycler 2320EXT at international conference ]]> http://www.proactiveinvestors.com/companies/news/128175/pressure-biosciences-unveils-barocycler-2320ext-at-international-conference-128175.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) on Wednesday unveiled its latest addition to its product line based on a patented and powerful pressure cycling technology ("PCT") platform, the Barocycler 2320EXTREME ("2320EXT").

The product unveiling took place during the recent annual conference of the American Society for Mass Spectrometry ("ASMS") in San Antonio, Texas. 

Pressure BioSciences also announced that scientists from six separate research groups made presentations on the company's PCT-based product line at the same international conference.

Results presented indicated that the company's PCT-based instruments and consumables, when used in the preparation of samples for mass spectrometric analysis, resulted in critically enabling qualitative and quantitative improvements and/or improved time or cost efficiency.

Presentations were made by scientists from the Children's Medical Research Institute (Sydney, Australia), the Johns Hopkins University School of Medicine, the Center for Food Safety and Applied Nutrition - Food and Drug Administration (FDA/CFSAN), Northwestern University, and Pressure BioSciences together with Protifi LLC.

The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide.  The Company took advantage of this opportunity to unveil the Barocycler 2320EXTREME. This addition to PBI's product line was designed with a number of new and enhanced features and benefits that should enable scientists better access to the biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, with the potential to result in new biological insights and discoveries, and rapid growth for PBI.  The Barocycler 2320EXT is expected to become the centerpiece of the recently announced co-marketing agreement with global life sciences analytical technologies leader SCIEX.

"Our participation in the recent ASMS Conference greatly exceeded our expectations, both in relation to the unveiling of the new Barocycler 2320EXT, and to the number and content of presentations by well-respected scientific groups on the advantages/benefits of our PCT-based product line when used in the critical area of sample preparation," said Dr. Nate Lawrence, Vice President of Marketing and Sales.

"We had nearly 1,000 attendees visit our exhibition booth and hospitality suite.  A number of these visitors were genuinely interested in learning about the advantages of PCT, and the features and benefits of the new Barocycler 2320EXT.  We are actively following up with these contacts, and expect that some of these scientists/groups will become PBI customers in the near future," he added.

]]>
Wed, 13 Jul 2016 14:56:00 -0400 http://www.proactiveinvestors.com/companies/news/128175/pressure-biosciences-unveils-barocycler-2320ext-at-international-conference-128175.html
<![CDATA[News - Pressure Biosciences preps for up-list on US exchanges after Q1 earnings ]]> http://www.proactiveinvestors.com/companies/news/126118/pressure-biosciences-preps-for-up-list-on-us-exchanges-after-q1-earnings-126118.html Pressure Biosciences Inc (OTCMKTS:PBIO) laid out its 2016 goals on Wednesday which include implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT.

The company also wants to complete the manufacture of the Barocycler 2320 EXTREME and begin the commercialisation phase for this computer-driven, new pressure-generating instrument during the second quarter, as well as secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.

The near-term goals accompanied the company reporting its first quarter earnings results which saw products and services revenue increases 26% year-on-year to $510,478 and sales of Instruments and Consumables rise to $454,350 from $359,364.

Pressure BioSciences develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn life sciences sample preparation market.

The company recorded a net loss of $5.95mln in the three months to March 31, from $2mln in the same period a year ago.

"We believe the market for our pressure-based products (instruments and consumables) is large, diverse, and growing.  In order to successfully increase and expand our penetration into this market, it is essential that we continue to increase market exposure and acceptance of our novel PCT-based product line," said Richard T. Schumacher, President and CEO of PBI.

"We believe the major operational accomplishments of the 2016 first quarter – especially the co-marketing agreement with SCIEX and the development of the new Barocycler 2320EXTREME – will play key roles in increasing our visibility, acceptance, and success in penetrating this market, which will subsequently help PBI achieve rapid and dramatic growth in the near future," he added.

]]>
Wed, 18 May 2016 14:52:00 -0400 http://www.proactiveinvestors.com/companies/news/126118/pressure-biosciences-preps-for-up-list-on-us-exchanges-after-q1-earnings-126118.html
<![CDATA[News - Pressure BioSciences to host teleconference to discuss results ]]> http://www.proactiveinvestors.com/companies/news/126054/pressure-biosciences-to-host-teleconference-to-discuss-results-126054.html Pressure BioSciences, Inc. (OTCMKTS:PBIO) on Tuesday announced the company will host a teleconference to discuss its first quarter 2016 financial results and to provide a business update.

The teleconference will include a company presentation followed by a question & answer period on Wednesday, May 18, at 4:30 PM Eastern Daylight Time (EDT).

]]>
Tue, 17 May 2016 15:54:00 -0400 http://www.proactiveinvestors.com/companies/news/126054/pressure-biosciences-to-host-teleconference-to-discuss-results-126054.html
<![CDATA[News - No pressure as Pressure BioSciences admitted to Richmond Club Index ]]> http://www.proactiveinvestors.com/companies/news/124719/no-pressure-as-pressure-biosciences-admitted-to-richmond-club-index-124719.html Pressure BioSciences Inc (OTCMKTS:PBIO) has been added to the prestigious Richmond Club Index, which has outperformed the S&P 500 Index by an average of 11% each year since its inception ten years ago, the company announced on Tuesday.

The Richmond Club boasts roughly 550 members, comprised of a mix of investment advisors, fund managers, analysts, and members of the media.

Pressure BioSciences is a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry.

Inclusion in the Richmond Club Index is difficult to achieve.  To be invited, the Richmond Club initially screens thousands of publicly-traded companies, chooses a few to interview, then selects the best company among the finalists that it believes is the most undervalued relative to its peers, and also offers excellent growth potential.

"This new investor recognition, building upon PBI's recent growth momentum together with important financial, strategic marketing, and new product achievements, lead us to believe that 2016 will be our most successful year to date," said Richard T. Schumacher, President and CEO of PBI.

 

]]>
Tue, 12 Apr 2016 14:56:00 -0400 http://www.proactiveinvestors.com/companies/news/124719/no-pressure-as-pressure-biosciences-admitted-to-richmond-club-index-124719.html
<![CDATA[News - Pressure Biosciences share offering over-subscribed ]]> http://www.proactiveinvestors.com/companies/news/124588/pressure-biosciences-share-offering-over-subscribed-124588.html All five board members of Pressure BioSciences Inc (OTCMKTS:PBIO) put their hands in their pockets to support the pressure cycling technology (PCT) specialist's fund-raising.

The company announced the receipt of $769,667 in the final close of its $5mln private investment in public equity (PIPE) financing .

The final closing increased the total raised in the offering to $6,329,667, comfortably above the company's goal of $5mln. Pressure BioSciences netted $719,049 in cash from the final close and $5,101,049 in cash from the total offering.

Under the terms of the offer, the company issued senior secured convertible debentures with a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable into shares of restricted common stock at an exercise price of $0.40 per share.

Richard Schumacher, president and chief executive officer of Pressure BioSciences, said the cash raised had enabled the company to accomplish a number of key goals during the latter half of 2015 and the first three months of 2016. These include:

the elimination of all variable-rate debt;

the development of the new Barocycler NEP2320 Extreme, designed specifically for use in mass spectrometry sample preparation, including AB Sciex's SWATH-MS mass spectrometric system;

the support of new marketing initiatives to potential customers worldwide that have already begun to show positive results through increased requests for instrument/consumable information and quotations);

the ability to support multiple scientific collaborators, many of whom are considered key opinion leaders, whose studies readily highlight the advantages of the PCT platform to potential customers worldwide;

the ability to strongly support the recently announced co-marketing agreement with SCIEX, a leader in life sciences analytical technologies worldwide.

“We are very pleased to have not only completed the $5mln financing, but to have completed it with approximately $1.3mln in over-subscriptions.  We thank all investors who participated in the offering for their faith and trust in the PBI Team and in our patented and enabling pressure cycling technology ... platform," Schumacher said.

]]>
Fri, 08 Apr 2016 08:12:00 -0400 http://www.proactiveinvestors.com/companies/news/124588/pressure-biosciences-share-offering-over-subscribed-124588.html